NICE - National Institute for Health and Care Excellence

We’ve published a new set of routing criteria for our Highly Specialised Technology (HST) programme: https://lnkd.in/et3yfubS    NICE’s chief medical officer, prof Jonathan Benger explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases, and why effective routing is essential to getting the best care to patients across the NHS: https://lnkd.in/e7y7YTGn

Thank you to everyone who participated in #NICEConf25.     We'd value your key takeaways from the conference – what discussions or insights will inform your work going forward?

Endometriosis affects millions and diagnosis can take years.   In this episode of NICETalks, we explore our guideline and quality stardard, as well as #EndometriosisExplained—a global push for awareness & action.   🔗Listen now: https://lnkd.in/ejk_ahwm   #EndometriosisAwarenessMonth

Innovation is vital in healthcare to meet patients' evolving needs. Since launching in 2022, the NHS Innovation Service has assessed over 1,000 healthcare innovations, offering tailored, end-to-end support from expert organisations. Have an innovation? Learn more: innovation.nhs.uk #NHSInnovation

Have you subscribed to our newsletters? Keeping you up to date with important developments at NICE. We bring you our latest news, features and guidance straight to your inbox. There’s tailored newsletters for those working in: 🔹health and social care 🔹life sciences 🔹primary care Sign up⤵️ https://lnkd.in/eGNvAbzc

📣 Applications are now open for the new UK-wide Innovative Licensing and Access Pathway (ILAP)📣 The ILAP is now open for Innovation Passport applications. Products that meet all the eligibility criteria and which best meet the selection criteria will be awarded an Innovation Passport to enter the ILAP. 💡In case you missed it, the ILAP is a unique initiative which aims to accelerate the time to patient care for transformative new medicines and drug-device combinations, facilitating patient access by providing a single integrated platform for sustained collaborative working between the developer, the Regulator (MHRA), the UK Health Technology Assessment (HTA) bodies and the National Health Service (NHS), as well as patients. The ambition of this new pathway is to support the rapid development of transformative medicines that can be introduced into the NHS to address unmet clinical needs for patients and healthcare professionals at the earliest opportunity, without compromising on standards of safety, quality, and effectiveness.   To apply for an Innovation Passport, visit ➡️ https://bit.ly/42jluhC   Read the full guidance for the refreshed ILAP here ➡️ https://bit.ly/42zC9y1 Watch the recording of the ILAP refresh webinar here ➡️ https://bit.ly/3DZNhKP

One-off CAR T-cell therapy for large B-cell lymphoma (lisocabtagene maraleucel) recommended in final guidance published today. Learn more: https://lnkd.in/e63WXzUx

📢New treatment recommended for Lennox-Gastaut syndrome in NICE final guidance. 1,400 people living with this rare form of epilepsy that typically begins in childhood are set to benefit from fenfluramine. Learn more: https://lnkd.in/e8csKh-7

Every innovation journey has unique challenges. That's why we offer a broad range of services that match your specific needs. Partner with us for support that's shaped around you. Get in touch: https://lnkd.in/e_yvFk6t

NICE recommends blinatumomab with chemotherapy for Philadelphia-chromosome-negative CD19+ B-precursor acute lymphoblastic leukaemia with no minimal residual disease. Learn more: https://lnkd.in/eF77QBQj